386 related articles for article (PubMed ID: 32479130)
21. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
22. Myelodysplastic Syndromes: Diagnosis and Treatment.
Steensma DP
Mayo Clin Proc; 2015 Jul; 90(7):969-83. PubMed ID: 26141335
[TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
25. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
26. New investigational combinations for higher-risk MDS.
Koenig KL; Borate U
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):368-374. PubMed ID: 36485141
[TBL] [Abstract][Full Text] [Related]
27. Hypomethylating agents and chemotherapy in MDS.
Adès L; Santini V
Best Pract Res Clin Haematol; 2013 Dec; 26(4):411-9. PubMed ID: 24507817
[TBL] [Abstract][Full Text] [Related]
28. How we manage adults with myelodysplastic syndrome.
Fenaux P; Platzbecker U; Ades L
Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
[TBL] [Abstract][Full Text] [Related]
29. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
[TBL] [Abstract][Full Text] [Related]
30. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Lucero J; Al-Harbi S; Yee KWL
Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
[TBL] [Abstract][Full Text] [Related]
31. Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?
Sockel K; Platzbecker U
Drugs; 2018 Dec; 78(18):1873-1885. PubMed ID: 30467725
[TBL] [Abstract][Full Text] [Related]
32. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Wang C; Sallman DA
Curr Treat Options Oncol; 2023 May; 24(5):387-408. PubMed ID: 36966266
[TBL] [Abstract][Full Text] [Related]
33. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
34. [Updated treatment strategies for myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2022; 63(6):660-666. PubMed ID: 36184521
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
Kewan T; Stahl M; Bewersdorf JP; Zeidan AM
Curr Hematol Malig Rep; 2024 Jun; 19(3):138-150. PubMed ID: 38632155
[TBL] [Abstract][Full Text] [Related]
37. Myelodysplastic syndromes: therapy and outlook.
Lyons RM
Am J Med; 2012 Jul; 125(7 Suppl):S18-23. PubMed ID: 22735747
[TBL] [Abstract][Full Text] [Related]
38. An update on the treatment of myelodysplastic syndromes.
Kurtin SE; Demakos EP
Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
[TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic syndromes: what do hospitalists need to know?
Zeidan AM; Faltas B; Douglas Smith B; Gore S
J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
Dan C; Chi J; Wang L
Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
